Antonio Bertoletti is the founder of Lion TCR. Lion TCR has raised $60M in total funding. Latest round: Series B. Based in Singapore, Singapore.
Antonio Bertoletti is the Scientific Founder of Lion TCR, a clinical-stage biotechnology company focused on TCR-T cell therapy for cancers and infectious diseases in Asia. He is also a professor and the Cellular Immunotherapy and Infectious Diseases Lead for the SingHealth-Duke-NUS Cell Therapy Centre.
Full founder directory · Investor directory · Company funding database · Fundraising library